Program
ABSK141
A development code. Also written as “ABSK141-400mg”, “ABSK141-Recommended Dose for Expansion (RDE)” and “ABSK141-800mg”.
Its studies are led by Abbisko Cayman.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Abbisko Cayman | 11 open or running | phase 2since Jan 28, 2026 | Jan 28, 2026 | Dec 30, 2028phase 2 · NCT07417189 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 28, 2026First study: phase 2 study in Solid Tumors, AdultFirst studyNCT07417189 · 401 planned · China
Ahead
- Dec 30, 2028Primary completion: phase 2 study in Solid Tumors, AdultNCT07417189
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07417189Solid Tumors, Adult · China | 2 | Recruiting | Dec 30, 2028 | 401 |
How it is read
Names in the registry
- “ABSK141-400mg”, 1 entry
- “ABSK141-Recommended Dose for Expansion (RDE)”, 1 entry
- “ABSK141-800mg”, 1 entry
- “ABSK141-1200mg”, 1 entry
- “ABSK141-Recommended Phase 2 dose (RP2D)”, 1 entry
Codes read as this program: ABSK141.
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.